AI-Powered Real-Time Barrett’s Surveillance and Early Esophageal Adenocarcinoma (EAC) Detection
DovaVision BE (in development) aims to transform Barrett’s Esophagus (BE) surveillance to reduce missed lesions, unnecessary biopsies, and costs, while improving early EAC detection and clinical outcomes.
Dynamic Frame Level Detection
Real-time AI inference to ensure subtle lesions aren’t missed during live procedures.
Granular Mapping
Differentiates dysplastic vs. non-dysplastic BE, delineates Barrett’s islands for precise biopsy targeting.
Integrated QA and Reporting
Automated, objective outputs for surveillance, quality assurance, and treatment planning.
FDA Breakthrough Device Designation
Recognized by the FDA as a Breakthrough Device for advancing Barrett’s surveillance and early EAC detection.
FOR CLINICAL PRACTICE
By identifying high-risk lesions earlier, DovaVision BE reduces diagnostic delays , addresses miss rates in current surveillance protocols, and supports earlier diagnosis of EAC, improving survival and quality of care.
By distinguishing dysplastic from non-dysplastic tissue, DovaVision BE improves adherence to biopsy protocols, reduces unnecessary sampling, and decreases costs while ensuring clinically relevant tissue is collected.
The system seamlessly integrates into endoscopy workflows with automated overlays and QA, requiring no internet connection. This reduces manual workload and enables adoption without disrupting clinical practice.
Expert-level detection and mapping reduces variability between operators and centers, ensuring reliable surveillance and treatment planning that scales across hospitals and clinical networks.